Atlas FDA

AeroPace® System

FDA premarket approval P240012 · decided 2024-12-04

Approval details

PMA number
P240012
Trade name
AeroPace® System
Generic name
Transvenous temporary phrenic nerve stimulator
Applicant
Lungpacer Medical USA, Inc.
Date received
2024-04-08
Decision date
2024-12-04
Days to decision
240 days
Decision code
APPR
Product code
SDL
Advisory committee
Anesthesiology
Expedited review
No
Location
Exton, PA
Statement
Approval for AeroPace® System. The AeroPace System is indicated to improve weaning success – increase weaning, reduce ventilator days, and reduce reintubation - in patients ages 18 years or older on mechanical ventilation >= 96 hours and who have not weaned.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.